Alpha Cognition Announces Voluntary Delisting from CSE

Rhea-AI Summary

Alpha Cognition (NASDAQ: ACOG) has announced its voluntary delisting from the Canadian Securities Exchange (CSE), effective at the close of trading on December 17, 2024. The company's common shares will continue to trade exclusively on the Nasdaq Capital Market under the symbol 'ACOG'. This decision comes in connection with the company's existing Nasdaq listing.

Positive

• Consolidation to Nasdaq listing may increase visibility to U.S. investors
• Potential reduction in listing-related expenses by maintaining single exchange presence

Negative

• Reduced accessibility for Canadian investors
• Potential decrease in trading volume from Canadian market exit

Insights

Financial Analyst

The voluntary delisting from CSE while maintaining NASDAQ listing represents a strategic consolidation of Alpha Cognition's trading presence. With a relatively small market cap of $89.1M, concentrating trading volume on NASDAQ could potentially improve liquidity and reduce administrative costs associated with dual listing. This move aligns with many small-cap biotech companies' preference for NASDAQ as their primary trading venue, given its stronger ecosystem for healthcare and biotech stocks. However, Canadian investors may face increased complexity in trading the stock, potentially impacting the local investor base. The consolidation to NASDAQ maintains access to U.S. capital markets, which is important for biotech companies requiring significant funding for drug development.

VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)-- Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, or the “Company”), announces that in connection with the Company’s listing on the Nasdaq Capital Market the Company will voluntarily delist its common shares from the Canadian Securities Exchange.

The shares will be delisted from the Canadian Securities Exchange at the close of trading on December 17, 2024. The Company’s common shares will continue to trade on the Nasdaq under the symbol “ACOG”.

About Alpha Cognition Inc.

Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options.

ZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ZUNVEYL’s active metabolite is differentiated from donepezil and rivastigmine in that it improves the function of neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. Benzgalantamine is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI.

Forward-looking Statements: This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241212186439/en/

For further information:

Michael McFadden, CEO

Tel: 1-858-344-4375

info@alphacognition.com

Source: Alpha Cognition Inc.

FAQ

When will Alpha Cognition (ACOG) delist from the Canadian Securities Exchange?

Alpha Cognition will delist from the Canadian Securities Exchange at the close of trading on December 17, 2024.

Will ACOG continue trading after CSE delisting?

Yes, ACOG will continue trading on the Nasdaq Capital Market under the symbol 'ACOG'.

Why is Alpha Cognition (ACOG) delisting from the CSE?

The delisting is voluntary and comes in connection with the company's listing on the Nasdaq Capital Market, suggesting a strategic focus on the U.S. market.

What happens to ACOG shares held on the CSE after December 17, 2024?

Shares will continue to be tradable but will only be available for trading on the Nasdaq Capital Market under the symbol ACOG.